X4 Pharmaceuticals (XFOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula ...

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on AbSci (ABSI – Research Report). The associated price ...

Ocugen is a biopharmaceutical company that discovers ... a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center. Give your ...

Ocugen is a biopharmaceutical company that discovers ... a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center. Give your ...

Target or technology pipeline and corporate benchmark analysis and assessment reports can be prepared according to the specifications of the client from the pharmaceutical or biotechnology industry.

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Ocugen, Inc. has announced the commencement of its Phase 1 clinical trial for OCU200, targeting diabetic macular edema (DME). The trial, which has begun dosing its first patient, aims to evaluate ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...